



COPY OF PAPERS
ORIGINALLY FILED

10/ Reg for
Recons

09/732,241

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mathai Mammen et al.	Examiner:	Raymond Covington
Serial No.:	09/732,241	Group Art Unit:	1625
Filed:	December 7, 2000	Docket:	1343.011US1
Title:	THERAPEUTIC CARBAMATES		

Best
9-6-02

RESPONSE UNDER 37 CFR § 1.111

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
SEP 04 2002
TECH CENTER 1600/2900

Sir:

In response to the Office Action mailed on May 30, 2002, please consider the following remarks.

REMARKS

Applicants respectfully request reconsideration of the rejection of the claims in view of the remarks presented herein. Claims 1-52 are pending.

§112 Rejections

Claim 22 was rejected under 35 U.S.C. § 112, second paragraph, as indefinite. This rejection is respectfully traversed.

The Examiner stated that the phrase "any one of formula A1-A590 shown herein above" renders claim 22 indefinite. It is respectfully pointed out that claim 22 was amended in the previous amendment and response filed 07 February 2002; claim 22 now reads, "The compound of claim 1 or 2 wherein L₂ has any one of the formulas A1-A590 in Table 1." Thus, claim 22 does not include the phrase identified by the Examiner as indefinite. Accordingly, withdrawal of the rejection of claim 22 under 35 U.S.C. § 112, second paragraph, is respectfully requested.

The following remarks are also provided in support of the patentability of claim 22. Claim 22 recites specific values for L₂ and depends from claims 1 and 2. Both claims 1 and 2 recite compounds comprising a group L₂. Thus, there is antecedent basis for "L₂." Additionally, formulas A1-A590 fall within the definition of L₂ recited in claims 1 and 2. Thus, it is respectfully submitted that there is sufficient antecedent basis for the specific L₂ values recited in